Stepped Care aiTBS 2 Depression Study (Ghent)

Status Completed

Clinical Trial Summary

Antidepressant-free unipolar melancholic depressed patients (at least stage 2 treatment-resistant) will be selected by a certified psychiatrist, who will administer (semi-)structured clinical interviews. Because concomitant antidepressant treatment can confound outcome results, all patients will go through a medication washout before entering the study and they will be free from any antidepressant, neuroleptic and mood stabilizer for at least two weeks before entering the treatment protocol. Only habitual benzodiazepine agents will be allowed. STEP 1: Patients will be treated with in total 20 accelerated intermittent Theta Burst Stimulation (aiTBS) sessions (3000 pulses/session) over the left dorsolateral prefrontal cortex, which will be spread over 4 days. On each stimulation day, a given patient will receive 5 sessions with a between-session delay of 15 minutes. Patients will be randomized to receive either the real aiTBS or sham treatment (first week). However, the sham group will receive real aiTBS treatment with 10 days' time interval. The investigators expect that real aiTBS treatment and not sham will result in a significant and clinical meaningful response. STEP 2: To optimize treatment and reduce relapse following the iTBS treatment, in a stepped care approach, all patients then continue with cognitive control training (CCT) ten days later. This CCT consists of 20 sessions, spread over 4 weeks. Patients will be randomized to receive either real CCT or a control training. During this follow-up treatment, all patients will be prescribed antidepressant medication (SSRI) again. As iTBS treatment effects are known to decline over time, the investigators expect that combining aiTBS with a follow-up CCT therapy will stabilize the clinical effects over time compared to receiving the iTBS treatment alone. For baseline comparisons, patients will be closely matched for gender and age with never-depressed, medication-free healthy volunteers. No volunteer will undergo treatment.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Depression
Depressive Disorder
Depressive Disorder, Major
Depressive Disorder, Treatment-Resistant
Melancholia
Treatment Resistant Depression

Clinical Trial Details

NCT number	NCT03288675
Study type	Interventional
Source	University Hospital, Ghent
Contact
Status	Completed
Phase	N/A
Start date	October 5, 2017
Completion date	December 31, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05915013` - Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response	Phase 1
Completed	`NCT04469322` - Pharmacogenetic Implementation Trial in Veterans With Treatment Refractory Depression	N/A
Recruiting	`NCT05415397` - Treating Immuno-metabolic Depression With Anti-inflammatory Drugs	Phase 3
Recruiting	`NCT05988333` - Psychoeducational Intervention for Families With a Member Affected by Major Depression	N/A
Completed	`NCT02919501` - Study of the Efficacy and Safety of Initial Administration of 17 mg Vortioxetine Intravenously With 10 mg/Day Vortioxetine Orally in Patients With Major Depressive Disorder	Phase 2
Completed	`NCT00976560` - Clinical Study to Test a New Drug to Treat Major Depression	Phase 2
Recruiting	`NCT05518149` - A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD)	Phase 3
Not yet recruiting	`NCT06303076` - Tizanidine vs. Zolpidem in Primary Insomnia: A Randomized Trial	Phase 4
Not yet recruiting	`NCT05901571` - Acupuncture and Escitalopram for Treating Major Depression Clinical Study	N/A
Suspended	`NCT02546024` - Predictors of Treatment Response in Late-onset Major Depressive Disorder	N/A
Completed	`NCT02452892` - Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)	N/A
Completed	`NCT01583400` - Enhanced Collaborative Depression Treatment in Primary Care: The RESPECT-D-E Trial	N/A
Completed	`NCT01407575` - Buprenorphine for Treatment Resistant Depression	Phase 3
Completed	`NCT01152996` - Safety and Tolerability of Vortioxetine (LuAA21004) - Open Label Extension Study	Phase 3
Enrolling by invitation	`NCT00762866` - Psychiatric Genotype/Phenotype Project Repository
Completed	`NCT00366652` - Study Evaluating the Effects of DVS SR and Duloxetine on the Pharmacokinetics of Desipramine in Healthy Subjects	Phase 3
Completed	`NCT00384033` - Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) In The Treatment Of Major Depressive Disorder	Phase 3
Completed	`NCT00369343` - Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) Versus Placebo in Peri- and Postmenopausal Women	Phase 3
Completed	`NCT00149643` - Effectiveness of Fluoxetine in Young People for the Treatment of Major Depression and Marijuana Dependence	Phase 2
Completed	`NCT00316160` - Sexual Functioning Study With Antidepressants	Phase 4

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Stepped Care aiTBS 2 Depression Study (Ghent) — aiTBS2-Ghent

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms